Cognition in novice ecstasy users with minimal exposure to other drugs: A prospective cohort study

Archives of General Psychiatry

Volumn 64, Issue 6, 2007, Pages 728-736

  Schilt, Thelma ^a,b   De Win, Maartje M L ^b   Koeter, Maarten ^a,b   Jager, Gerry ^c   Korf, Dirk J ^b   Van Den Brink, Wim ^a,b   Schmand, Ben ^b  

^a AMSTERDAM INSTITUTE FOR ADDICTION RESEARCH   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CANNABIS; RECREATIONAL DRUG;

ADULT; ARTICLE; ATTENTION; COGNITION; CONTROLLED STUDY; DEPTH PERCEPTION; DRUG ABUSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; RECALL; RECOGNITION; RISK; STATISTICAL SIGNIFICANCE; VERBAL MEMORY; VISUAL MEMORY; WORKING MEMORY;

ADULT; ATTENTION; CANNABIS; COGNITION; COGNITION DISORDERS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEMORY; MEMORY DISORDERS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NETHERLANDS; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; RISK FACTORS; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; VERBAL BEHAVIOR;

EID: 34249951339     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.64.6.728     Document Type: Article

References (90)

1. Hatzidimitriou G, McCann UD, Ricaurte GA. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4- methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci. 1999;19:5096-5107.
2. Ricaurte GA, Martello AL, Katz JL, Martello MB. Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J Pharmacol Exp Ther. 1992;261:616-622.
3. Ricaurte GA, DeLanney LE, Irwin I, Langston JW. Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res. 1988;446:165-168.
4. Colado MI, Murray TK, Green AR. 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br J Pharmacol. 1993;108:583-589.
5. Ricaurte GA, Yuan J, McCann UD. (+/-)3,4-Methylenedioxymethamphetamine ("Ecstasy")-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology. 2000;42:5-10.
6. Schmidt CJ, Wu L, Lovenberg W. Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue. Eur J Pharmacol. 1986;124:175-178.
7. O'Shea E, Granados R, Esteban B, Colado MI, Green AR. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA("ecstasy"). Neuropharmacology. 1998;37:919-926.
8. Fischer C, Hatzidimitriou G, Wlos J, Katz J, Ricaurte G. Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). J Neurosci. 1995;15:5476-5485.
9. Gerra G, Zaimovic A, Giucastro G, Maestri D, Monica C, Sartori R, Caccavari R, Delsignore R. Serotonergic function after (+/-)3,4-methylene- dioxymethamphetamine ("Ecstasy") in humans. Int Clin Psychopharmacol. 1998;13:1-9.
10. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet. 1998;352:1433-1437.
11. Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ("ecstasy") users. Br J Psychiatry. 1999;175:63-69.
12. Reneman L, Booij J, Schmand B, van den Brink W, Gunning B. Memory disturbances in "Ecstasy" users are correlated with an altered brain serotonin neurotransmission. Psychopharmacology (Berl). 2000;148:322-324.
13. Reneman L, Booij J, de Bruin K, Reitsma JB, de Wolff FA, Gunning WB, den Heeten GJ, van den Brink W. Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet. 2001;358:1864-1869.
14. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev. 2003;55:463-508.
15. Cohen Z, Bonvento G, Lacombe P, Hamel E. Serotonin in the regulation of brain microcirculation. Prog Neurobiol. 1996;50:335-362.
16. Meneses A. 5-HT system and cognition. Neurosci Biobehav Rev. 1999;23:1111-1125.
17. Parrott AC. Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol. 2001;16:557-577.
18. Back-Madruga C, Boone KB, Chang L, Grob CS, Lee A, Nations H, Poland RE. Neuropsychological effects of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) in recreational users. Clin Neuropsychol. 2003;17:446-459.
19. Verbaten MN. Specific memory deficits in ecstasy users? the results of a meta-analysis. Hum Psychopharmacol. 2003;18:281-290.
20. Gouzoulis-Mayfrank E, Daumann J. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? Addiction. 2006;101:348-361.
21. Krystal JH, Price LH, Opsahl C, Ricaurte GA, Heninger GR. Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function? Am J Drug Alcohol Abuse. 1992;18:331-341.
22. Bolla KI, McCann UD, Ricaurte GA. Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology. 1998;51:1532-1537.
23. Parrott AC, Lees A, Garnham NJ, Jones M, Wesnes K. Cognitive performance in recreational users of MDMA of "ecstasy": evidence for memory deficits. J Psychopharmacol. 1998;12:79-83.
24. Morgan MJ. Memory deficits associated with recreational use of "ecstasy" (MDMA). Psychopharmacology (Berl). 1999;141:30-36.
25. Bhattachary S, Powell JH. Recreational use of 3,4- methylenedioxymethamphetamine (MDMA) or "ecstasy": evidence for cognitive impairment. Psychol Med. 2001;31:647-658.
26. Zakzanis KK, Young DA. Memory impairment in abstinent MDMA ("Ecstasy") users: a longitudinal investigation. Neurology. 2001;56:966-969.
27. McCardle K, Luebbers S, Carter JD, Croft RJ, Stough C. Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology (Berl). 2004;173:434-439.
28. Reneman L, Lavalaye J, Schmand B, de Wolff FA, van den Brink W, den Heeten GJ, Booij J. Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): preliminary findings. Arch Gen Psychiatry. 2001;58:901-906.
29. Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L, Nebeling B, Schmoldt A. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology (Berl). 2003;167:85-96.
30. Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, Pelz S, Becker S, Kunert HJ, Fimm B, Sass H. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatry. 2000;68:719-725.
31. Verkes RJ, Gijsman HJ, Pieters MS, Schoemaker RC, de Visser S, Kuijpers M, Pennings EJ, de Bruin D, Van de Wijngaart G, Van Gerven JM, Cohen AF. Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology (Berl). 2001;153:196-202.
32. Wareing M, Fisk JE, Murphy P, Montgomery C. Verbal working memory deficits in current and previous users of MDMA. Hum Psychopharmacol. 2004;19:225-234.
33. McCann UD, Mertl M, Eligulashvili V, Ricaurte GA. Cognitive performance in (+/?) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users: a controlled study. Psychopharmacology (Berl). 1999;143:417-425.
34. Wareing M, Fisk JE, Murphy PN. Working memory deficits in current and previous users of MDMA ("ecstasy"). Br J Psychol. 2000;91:181-188.
35. Rodgers J. Cognitive performance amongst recreational users of "ecstasy." Psychopharmacology (Berl). 2000;151:19-24.
36. Simon NG, Mattick RP. The impact of regular ecstasy use on memory function. Addiction. 2002;97:1523-1529.
37. Vollenweider FX, Gamma A, Liechti M, Huber T. Is a single dose of MDMA harmless? Neuropsychopharmacology. 1999;21:598-600.
38. McCann UD, Ricaurte GA, Molliver ME. "Ecstasy" and serotonin neurotoxicity: new findings raise more questions. Arch Gen Psychiatry. 2001;58:907-908.
39. Morgan MJ. Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology (Berl). 2000;152:230-248.
40. Turner JJ, Parrott AC. "Is MDMA a human neurotoxin?": diverse views from the discussants. Neuropsychobiology. 2000;42:42-48.
41. Boot BP, McGregor IS, Hall W. MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks. Lancet. 2000;355:1818-1821.
42. Morgan JF. Toxic effect of MDMA on brain serotonin neurons. Lancet. 1999;353:1268-1269.
43. Curran HV. Is MDMA ("Ecstasy") neurotoxic in humans? an overview of evidence and of methodological problems in research. Neuropsychobiology. 2000;42:34-41.
44. Parrott AC. Human research on MDMA (3,4-methylene-dioxymethamphetamine) neurotoxicity:cognitiveandbehaviouralindicesofchange. Neuropsychobiology. 2000;42:17-24.
45. Halpern JH, Pope HG Jr, Sherwood AR, Barry S, Hudson JI, Yurgelun-Todd D. Residual neuropsychological effects of illicit 3,4- methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug Alcohol Depend. 2004;75:135-147.
46. Gouzoulis-Mayfrank E, Daumann J. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview. J Psychopharmacol. 2006;20:188-193.
47. Rycroft N, Golding JF. Cognitive performance in current occasional and exusers of Ecstasy (MDMA) and controls. J Psychopharmacol. 2002;16(suppl):a59.
48. De Win MM, Jager G, Vervaeke HK, Schilt T, Reneman L, Booij J, Verhulst FC, Den Heeten GJ, Ramsey NF, Korf DJ, Van den Brink W. The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance. Int J Methods Psychiatr Res. 2005;14:167-185.
49. Gronwall DM. Paced auditory serial-addition task: a measure of recovery from concussion. Percept Mot Skills. 1977;44:367-373.
50. Wechsler D. WAIS-R Manual. San Antonio, Tex: Psychological Corp; 1981.
51. Lindeboom J, Matto D. Digit series and Knox cubes as concentration tests for elderly subjects [in Dutch]. Tijdschr Gerontol Geriatr. 1994;25:63-68.
52. Rey A. L'examen clinique en psychologie. Paris, France: Presses Universitaires de France; 1964.
53. Van den Burg W, Saan RJ, Deelman BG. 15-woordentest: Provisional Manual. Groningen, the Netherlands: University Hospital; 1985.
54. Graham FK, Kendall BS. Memory-for-design: revised general manual. Percept Mot Skills. 1960;11:147-188.
55. Shepard RN, Metzler J. Mental rotation of three-dimensional objects. Science. 1971;171:701-703.
56. Benton AL, Varney NR, Hamsher KD. Visuospatial judgment: a clinical test. Arch Neurol. 1978;35:364-367.
57. Van de Wijngaart G, Braam R, de Bruin D, Fris M, Maalsté N, Verbraeck H. Ecstasy in het uitgaanscircuit [Ecstasy and the Dutch Rave Scene: A Socioepidemiologic Study on the Nature and Extent of, and the Risks Involved in Using Ecstasy and Other Party Drugs at Dance Events]. Utrecht, the Netherlands: Addiction Research Institute; 1997.
58. Nelson HE, O'Connell A. Dementia: the estimation of premorbid intelligence levels using the New Adult Reading Test. Cortex. 1978;14:234-244.
59. Schmand B, Bakker D, Saan R, Louman J. The Dutch Reading Test for Adults: a measure of premorbid intelligence level [in Dutch]. Tijdschr Gerontol Geriatr. 1991;22:15-19.
60. Tabachnick BG, Fidell L. Using Multivariate Statistics. Boston, Mass: Allyn & Bacon; 2001.
61. Bond AJ, Verheyden SL, Wingrove J, Curran HV. Angry cognitive bias, trait aggression and impulsivity in substance users. Psychopharmacology (Berl). 2004;171:331-339.
62. Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl). 2001;154:161-168.
63. Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, Obrocki J, Schulze O, Schmidt U, Clausen M. A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters. Am J Psychiatry. 2004;161:1181-1189.
64. Sala M, Braida D. Endocannabinoids and 3,4-methylenedioxymethamphetamine (MDMA) interaction. Pharmacol Biochem Behav. 2005;81:407-416.
65. Verdejo-Garcia AJ, Lopez-Torrecillas F, Aguilar de Arcos F, Perez-Garcia M. Differential effects of MDMA, cocaine, and cannabis use severity on distinctive components of the executive functions in polysubstance users: a multiple regression analysis. Addict Behav. 2005;30:89-101.
66. Dafters RI, Hoshi R, Talbot AC. Contribution of cannabis and MDMA ("ecstasy") to cognitive changes in long-term polydrug users. Psychopharmacology (Berl). 2004;173:405-410.
67. Croft RJ, Mackay AJ, Mills AT, Gruzelier JG. The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharmacology (Berl). 2001;153:373-379.
68. de Win MM, Schilt T, Reneman L, Vervaeke H, Jager G, Dijkink S, Booij J, van den Brink W. Ecstasy use and self-reported depression, impulsivity, and sensation seeking: a prospective cohort study. J Psychopharmacol. 2006;20:226-235.
69. Sumnall HR, Cole JC. Self-reported depressive symptomatology in community samples of polysubstance misusers who report Ecstasy use: a meta-analysis. J Psychopharmacol. 2005;19:84-92.
70. Gouzoulis-Mayfrank E, Thimm B, Rezk M, Hensen G, Daumann J. Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:819-827.
71. Fox HC, Toplis AS, Turner JJ, Parrott AC. Auditory verbal learning in drug-free Ecstasy polydrug users. Hum Psychopharmacol. 2001;16:613-618.
72. Parrott AC, Lasky J. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology (Berl). 1998;139:261-268.
73. Jacobsen LK, Mencl WE, Pugh KR, Skudlarski P, Krystal JH. Preliminary evidence of hippocampal dysfunction in adolescent MDMA ("ecstasy") users: possible relationship to neurotoxic effects. Psychopharmacology (Berl). 2004;173:383-390.
74. Reneman L, Schilt T, de Win MM, Booij J, Schmand B, van den Brink W, Bakker O. Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users. J Psychopharmacol. 2006;20:389-399.
75. Fox HC, McLean A, Turner JJ, Parrott AC, Rogers R, Sahakian BJ. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drugfree MDMA ("ecstasy") polydrug users. Psychopharmacology (Berl). 2002;162:203-214.
76. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther. 1987;241:338-345.
77. Molero-Chamizo A. 3,4-methylenedioxymethamphetamine ("ecstasy") : its long-term emotional and cognitive effects, and serotonin depletion [in Spanish]. Rev Neurol. 2005;41:108-114.
78. Ricaurte GA, McCann UD, Szabo Z, Scheffel U. Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). Toxicol Lett. 2000;112-113:143-146.
79. Buhot MC, Malleret G, Segu L. Serotonin receptors and cognitive behaviour: an update. IDrugs. 1999;2:426-437.
80. Hunter AJ. Serotonergic involvement in learning and memory. Biochem Soc Trans. 1989;17:79-81.
81. Meneses A, Hong E. Modification of 8-OH-DPAT effects on learning by manipulation of the assay conditions. Behav Neural Biol. 1994;61:29-35.
82. Harrison BJ, Olver JS, Norman TR, Burrows GD, Wesnes KA, Nathan PJ. Selective effects of acute serotonin and catecholamine depletion on memory in healthy women. J Psychopharmacol. 2004;18:32-40.
83. Topp L, Barker B, Degenhardt L. The external validity of results derived from ecstasy users recruited using purposive sampling strategies. Drug Alcohol Depend. 2004;73:33-40.
84. Drugs Informatie en Monitoring Systeem. Jaarbericht 2003. Utrecht, the Netherlands: DIMS/Trimbos-instituut; 2003.
85. Drugs Informatie en Monitoring Systeem. Jaarbericht 2004. Utrecht, the Netherlands: DIMS/Trimbos-instituut; 2004.
86. Nabben T, Benschop A, Korf DJ. Antenne 2004 Trends in alcohol, tabak en drugs bij jonge Amsterdammers. Amsterdam, the Netherlands: Rozenberg Publishers; 2005.
87. Stern Y, Zarahn E, Hilton HJ, Flynn J, DeLaPaz R, Rakitin B. Exploring the neural basis of cognitive reserve. J Clin Exp Neuropsychol. 2003;25:691-701.
88. Schmand B, Smit JH, Geerlings MI, Lindeboom J. The effects of intelligence and education on the development of dementia: a test of the brain reserve hypothesis. Psychol Med. 1997;27:1337-1344.
89. Valenzuela MJ, Sachdev P. Brain reserve and dementia: a systematic review. Psychol Med. 2006;36:441-454.
90. Satz P, Morgenstern H, Miller EN, Selnes OA, McArthur JC, Cohen BA, Wesch J, Becker JT, Jacobson L, D'Elia LF, van Gorp W, Visscher B. Low education as a possible risk factor for cognitive abnormalities in HIV-1: findings from the multicenter AIDS Cohort Study (MACS). J Acquir Immune Defic Syndr. 1993;6:503-511.